Here's a snip from a comment discussing the covid reinfection paper. The author is not saying that BA.4/5 will necessarily escape the Omicron BA.1 vaccines ("we don't have adequate data"), but his comments do make me wonder what will happen with BA.4/5.
>>>The Omicron BA.1-specific vaccine booster remedy?
The worry is centered about the immune escape of these subvariants, which was characterized in a
recent Nature paper with the conclusion “Together, our results indicate that Omicron may evolve mutations to evade the humoral immunity elicited by BA.1 infection, suggesting that BA.1-derived vaccine boosters may not achieve broad-spectrum protection against new Omicron variants.”
That is to say, besides vulnerability to reinfections, the Omicron BA.1 specific vaccines, due to become available this Fall, may not provide enhanced protection as anticipated. BA.4/5 are too different from BA.1 with respect to how our immune system sees them. Even the head of BioNTech has recently warned about the potential for further immune escape and the reduced impact of vaccines, including an Omicron-BA.1 specific one.
We are already seeing evidence of some less protection against severe Covid, that requiring hospitalization, with r
ecent reports of vaccine effectiveness, such as 77% in 21 United States hospitals among immunocompetent individuals with 3 shots. Recall the mRNA vaccine effectiveness vs. hospitalization was 95% through Delta. We don’t have adequate data for vaccine protection vs BA.4/5 yet, but it is certainly possible there will be some attrition which has fortunately not been noted between BA.1 and BA.2.<<< (emphasis added).
Why a new report is so troubling
erictopol.substack.com
He also asks in a twitter post why pan-beta-coronavirus vaccines and nasal vaccines are not being developed more aggressively:
I'm not sure what "the" answer is, but while attempting to find it I ran across this blog post from earlier this year which includes some interesting comments concerning the various known viruses and vaccine candidates. He concludes that broader vaccines should be possible.
>>>This means that when you talk about broader vaccine coverage, you could be referring to several different things. For the purposes of this blog post, I'll classify them as follows:
Type I Vaccines: generate immunity to all four genuses of coronavirus
Type II Vaccines: generate immunity to the betacoronaviruses
Type III Vaccines: generate immunity to the sarbecovirus (lineage B) betacoronaviruses
Type IV Vaccines: generate immunity to current and future variants of just the particular sarbecovirus we're dealing with, SARS-CoV-2.
. . .
There are actually several vaccines along this spectrum that are in the clinic, and I would roughly assign them this way:
Type I: None at the moment (that's a tall order) . . .
Type II:
DIOSynvax, from a Cambridge startup working with CEPI.
Type III: Walter Reed's
SpFN ferritin-nanoparticle vaccine.
GBP511 is coming along towards the clinic here, too.
Type IV: Gritstone Bio's GRT-
R910, ImmunityBio's
hAd5 S+N.
. . . There's no reason why broader coronavirus vaccines should be impossible to develop. . . .<<<
www.science.org